Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Cerus cancer, infectious news

CERS will restructure to focus on developing therapeutic vaccines against cancer and infectious diseases. The company said it will reduce its headcount by about 35% and its

Read the full 270 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE